|
Recently Approved Documents
Reagent Water in Clinical Laboratories (C3-A4); Statistical Quality Control Procedures (C24-A3); Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated from Aquatic Animals (M42-A); Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated from Aquatic Animals (M49-A); Molecular Diagnostic Methods for Genetic Diseases (MM1-A2)
C3-A4—Preparation and Testing of Reagent Water in the Clinical Laboratory; Approved Guideline – Fourth Edition
This document provides guidelines on water purified for clinical laboratory use; methods for monitoring water quality and testing for specific contaminants; and water
system design considerations.
Purchase here.
C24-A3—Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions; Approved Guideline – Third Edition
This guideline provides definitions of analytical intervals; planning of quality control procedures; and guidance for quality control applications.
Purchase here.
M42-A—Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline
This document provides the most up-to-date techniques for disk diffusion susceptibility testing of aquatic species isolates, and criteria for quality control testing.
Purchase here.
M49-A—Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline
This document provides guidance to clinical microbiology laboratories for standardized susceptibility testing of infrequently isolated or fastidious bacteria that are not presently included in CLSI documents M2, M7, or M11. The tabular information in this document presents the most current information for drug selection, interpretation, and quality control for the infrequently isolated or fastidious bacterial pathogens included in this guideline.
Purchase here.
MM1-A2—Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline – Second Edition
This document provides guidance for the use of molecular biologic techniques for clinical detection of heritable mutations associated with genetic disease.
Purchase here.
Our procedures have been designed to ensure that consensus has been achieved when a standard or guideline is published at the approved level. This means that a document has been rigorously reviewed by the authoring subcommittee, the area committee overseeing the project, the Board of Directors, and the medical-testing community that participates in the consensus process by carefully reviewing and commenting on the standard or guideline.
You may automatically receive or select approved-level documents as a member benefit. Find out more about joining CLSI: view membership options and benefits.
[
return to top ]
|
